| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Academic Unit and Polyposis Registry,*Saint Mark’s Hospital, Harrow; the Molecular and Population Genetics Laboratoryand the Human Cytogenetics Laboratory,Cancer Research United Kingdom, London; the Mutation Detection Laboratory,Cancer Research United Kingdom, Saint James’s University Hospital, Leeds; and the Department of Clinical Genetics,¶Cancer Research United Kingdom, Guy’s Hospital, London, United Kingdom
Studies of adenomatous polyposis coli (APC) mutations in familial adenomatous polyposis (FAP) have focused on large bowel disease. It has been found that: 1) germline APC mutations around codon 1300 are associated with severe colorectal polyposis; 2) somatic APC mutations in colorectal tumors tend to cluster approximately between codons 1250 and 1450; and 3) patients with germline mutations close to codon 1300 tend to acquire somatic mutations (second hits) in their colorectal polyps by allelic loss, whereas the tumors of other FAP patients have truncating second hits. Using new and published data, we have investigated how germline and somatic APC mutations influence the pathogenesis of upper gastrointestinal polyps in FAP. We have compared the results with those from colorectal disease. We found that somatic mutations in upper gastrointestinal polyps cluster approximately between codons 1400 and 1580. Patients with germline APC mutations after codon 1400 tend to show allelic loss in their upper gastrointestinal polyps; the tumors of other patients have truncating somatic mutations after codon 1400. Finally, patients with germline mutations after codon 1400 tend to have more severe duodenal polyposis (odds ratio, 5.72; 95% confidence interval, 1.13 to 28.89; P = 0.035). Thus, in both upper gastrointestinal and colorectal tumors, a specific region of the APC gene is associated with severe disease, clustering of somatic mutations, and loss of the wild-type allele. However, the region concerned is different in upper gastrointestinal and colorectal disease. The data suggest that loss of all APC SAMP repeats is probably necessary for duodenal and gastric tumorigenesis in FAP, as it is in colonic tumors. Compared with colonic tumors, however, retention of a greater number of ß-catenin binding/degradation repeats is optimal for tumorigenesis in upper gastrointestinal FAP.
This article has been cited by other articles:
 |
|
 |
|
  A. Milicic, L.-A. Harrison, R. A. Goodlad, R. G. Hardy, A. M. Nicholson, M. Presz, O. Sieber, S. Santander, J. H. Pringle, N. Mandir, et al. Ectopic Expression of P-Cadherin Correlates with Promoter Hypomethylation Early in Colorectal Carcinogenesis and Enhanced Intestinal Crypt Fission In vivo Cancer Res., October 1, 2008; 68(19): 7760 - 7768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ong, M. A. Alassas, P. N. Bogner, K. Bullard Dunn, W. Y. Chey, and J. F. Gibbs Total Gastrectomy for Gastric Dysplasia in a Patient With Attenuated Familial Adenomatous Polyposis Syndrome J. Clin. Oncol., July 20, 2008; 26(21): 3641 - 3642. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang and A. Chang Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer J. Med. Genet., March 1, 2007; 44(3): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Latchford, E. Volikos, V. Johnson, P. Rogers, N. Suraweera, I. Tomlinson, R. Phillips, and A. Silver APC mutations in FAP-associated desmoid tumours are non-random but not 'just right' Hum. Mol. Genet., January 1, 2007; 16(1): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mutoh, T. Akasu, M. Takahashi, N. Niho, T. Yoshida, T. Sugimura, and K. Wakabayashi Possible Involvement of Hyperlipidemia in Increasing Risk of Colorectal Tumor Development in Human Familial Adenomatous Polyposis Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L A A Brosens, J J Keller, G J A Offerhaus, M Goggins, and F M Giardiello Prevention and management of duodenal polyps in familial adenomatous polyposis Gut, July 1, 2005; 54(7): 1034 - 1043. [Full Text] [PDF]
|
|
|
|
|
|
N J H Sturt, M C Gallagher, P Bassett, C R Philp, K F Neale, I P M Tomlinson, A R J Silver, and R K S Phillips Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation Gut, December 1, 2004; 53(12): 1832 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kemp, C. Thirlwell, O. Sieber, A. Silver, and I. Tomlinson An update on the genetics of colorectal cancer Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R177 - R185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Bulow, J Bjork, I J Christensen, O Fausa, H Jarvinen, F Moesgaard, and H F A Vasen Duodenal adenomatosis in familial adenomatous polyposis Gut, March 1, 2004; 53(3): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M L Bisgaard, R Ripa, A L Knudsen, and S Bulow Familial adenomatous polyposis patients without an identified APC germline mutation have a severe phenotype Gut, February 1, 2004; 53(2): 266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Doglioni, S. Piccinin, S. Demontis, M. G. Cangi, L. Pecciarini, C. Chiarelli, M. Armellin, T. Vukosavljevic, M. Boiocchi, and R. Maestro Alterations of {beta}-Catenin Pathway in Non-Melanoma Skin Tumors: Loss of {alpha}-ABC Nuclear Reactivity Correlates with the Presence of {beta}-Catenin Gene Mutation Am. J. Pathol., December 1, 2003; 163(6): 2277 - 2287. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. R. Bruce Counterpoint: From Animal Models to Prevention of Colon Cancer. Criteria for Proceeding from Preclinical Studies and Choice of Models for Prevention Studies Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 401 - 404. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
